News

Technology News

Rosetta Genomics To Acquire PersonalizeDx

Friday, April 10, 2015 5:16:00 AM PDT | VentureDeal
   Princeton, New Jersey  --  Rosetta Genomics Ltd. (NASDAQ: ROSG) announced the intention to acquire CynoGen (dba PersonalizeDx) from Prelude Corporation.

PersonalizeDx is a molecular diagnostics and services company that serves community-based pathologists, urologists and other reference laboratories across the US.

Rosetta stands to gain proprietary test capabilities for bladder, prostate and lung cancer indications.

The acquisition price will be $2 million in cash, 500,000 ordinary shares of Rosetta Genomics Ltd. stock and additional undisclosed assets and related services.

The transaction is conditioned upon the closing of Prelude's acquisition of PersonalizeDx from a third party.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1